Aequus Pharmaceuticals Inc (AQS) — Cash Flow-to-Debt Ratio
Aequus Pharmaceuticals Inc (AQS) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CA$-21.22K could theoretically repay 0% of its total liabilities (CA$7.09 Million) in one year. Check Aequus Pharmaceuticals Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aequus Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Aequus Pharmaceuticals Inc across 12 annual periods. Also explore Aequus Pharmaceuticals Inc (AQS) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Aequus Pharmaceuticals Inc (2013–2024)
Year-by-year debt coverage analysis for Aequus Pharmaceuticals Inc. For market capitalisation and broader financial context, see market cap of Aequus Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.23x | CA$-1.66 Million | CA$7.26 Million | ▲ +46.5% |
| 2023 | -0.43x | CA$-2.29 Million | CA$5.38 Million | ▲ +32.9% |
| 2022 | -0.64x | CA$-1.95 Million | CA$3.07 Million | ▼ -38.8% |
| 2021 | -0.46x | CA$-1.17 Million | CA$2.56 Million | ▼ -45.7% |
| 2020 | -0.31x | CA$-804.91K | CA$2.56 Million | ▲ +50.8% |
| 2019 | -0.64x | CA$-1.63 Million | CA$2.55 Million | ▲ +92.2% |
| 2018 | -8.17x | CA$-2.57 Million | CA$314.90K | ▲ +21.3% |
| 2017 | -10.39x | CA$-3.81 Million | CA$366.84K | ▼ -73.2% |
| 2016 | -6.00x | CA$-4.47 Million | CA$744.41K | ▼ -78.9% |
| 2015 | -3.35x | CA$-3.84 Million | CA$1.15 Million | ▼ -82.9% |
| 2014 | -1.83x | CA$-1.36 Million | CA$744.51K | ▲ +88.1% |
| 2013 | -15.44x | CA$-876.06K | CA$56.74K | — |